(The) role of oncolytic virus as an immunomodulator in the microenvironment of colon cancer mouse model

Abstract

Immunotherapy for malignancy, which stimulates the patients’ own immune system to treat cancers with low toxicity, has been effective for MSI-high colorectal cancer. MSI-high diseases are less than 10% of overall colorectal cancer. Recent studies concentrate on synergizing the effect of immune checkpoint inhibitor by combination. Among them is an oncolytic virus. Tumor volumes after local injection of Oncolytic virus (OV) with anti-PD1 antibody decreased compared with OV alone or anti-PD1 antibody alone. Moreover, CD4+ T lymphocyte infiltration markedly increased as well as CD8+T lymphocyte infiltration when combination of OV and anti-PD1 antibody applied. OV can immunomodulate as well as replicate and kill the cancer cell. The combination of OV and anti-PD1 antibody can benefit for patients with tumors that are resistant to other therapies.